Aker BioMarine Antarctic, Oslo, Norway, has received confirmation from FDA that the agency has no objections to the company’s New Dietary Ingredient notification for Superba Kill Oil. FDA reviewed extensive toxicology and clinical research data obtained from animal and human testing, which provides support for evidence of safety. Aker BioMarine further provided detailed composition of krill oil, including the most extensive elucidation to date showing 69 distinct choline-containing phospholipids, believed to be responsible for the unique benefits of krill.

FDA has also accepted with no objections the notification of the company’s independent Generally Recognized As Safe (GRAS) determination for Superba Krill oil for use as a food ingredient.